Fig. 3.

DT administration during the FITC CHS sensitization phase results in exacerbated pathology. (A) Mice were administered a modified FITC CHS protocol with DT administered on day –1 and 1 [D–1 + D1 depletion (1)] or administered on day 5 [D5 depletion (2)]. (B) Ear swelling was measured 24 h post challenge in the FITC-treated ear. Data are pooled from three experiments (n = 8 CLEC4C-DTR⁺, n = 7 DTR^– littermates, n = 10 D–1 and D1 depleted CLEC4C-DTR⁺, n = 5 D5-depleted CLEC4C-DTR⁺). **P < 0.01; statistics by Student’s t test. Data in B are mean ± SD, and each symbol represents an individual mouse; ns, nonsignificant.